首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

1528928

外分泌胰臟功能不全治療市場 - 按治療（營養管理、胰酶替代療法）、藥物類型（Creon、Zenpep、Pancreaze、Ultresa、Viokace）、適應症、配銷通路- 全球預測（2024 - 2032）

Exocrine Pancreatic Insufficiency Treatment Market - By Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy), Drug Type (Creon, Zenpep, Pancreaze, Ultresa, Viokace), Indication, Distribution Channel - Global Forecast (2024 - 2032)

出版日期: 2024年05月07日 | 出版商:

Global Market Insights Inc. | 英文 298 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於老年人口不斷增加，外分泌胰臟功能不全治療市場規模預計從 2024 年到 2032 年複合年成長率將達到 6.6%。最近，臨床醫生正在開發和完善治療方法，以改善消化酵素的補充，以更好地吸收營養。這些治療有助於緩解老年患者的症狀，例如營養不良和胃腸道不適。

最近，正在進行的研究正在增強酶製劑和遞送方法，以根據個別患者的需求量身定做個性化酶療法，並改進診斷工具以早期檢測和管理外分泌胰腺功能不全（EPI）相關併發症。《2022 年世界人口展望》強調，與較年輕的年齡層相比，65 歲及以上人口的成長率更快。這一趨勢凸顯了人們更加重視改善外分泌胰臟功能不全的治療，以更好地滿足老年人的健康需求。

胰臟外分泌功能不全治療產業依治療方法、藥物類型、適應症、配銷通路及地區細分。

營養管理治療領域的市場佔有率將在2024年至2032年間錄得可觀的成長率。。專家們正在完善這些方法，將飲食調整與酵素補充劑結合起來，以提高療效和患者福祉。此外，研究工作正在帶來更具針對性的療法和最佳化的治療方案，以改善患者的治療結果和生活品質。

就分銷管道而言，預計2024年至2032年，線上藥局領域的EPI治療市場將出現顯著的複合年成長率。這是由於易於獲得治療，為患者提供了一個方便的平台來訂購治療吸收不良和消化問題等症狀所需的處方藥和酵素補充劑。藥劑師和醫療保健提供者正在積極利用這些平台來確保及時交付和患者關於治療依從性的教育。

由於醫療基礎設施的改善以及持續的藥物開發和創新努力，到 2032 年，亞太地區胰臟外分泌功能不全治療產業規模將創下顯著的複合年成長率。醫療機構積極升級，以更好地診斷和管理 EPI，從而提供更多必要的藥物和治療。研究人員和製藥公司正在開發新藥和治療方案，以提高療效和患者治療效果。藥物輸送系統和治療方法的持續創新確保亞太地區的 EPI 患者獲得最先進的護理，並提高該地區胰腺功能不全患者的生活品質。

產業生態系統分析
產業影響力
- 成長動力
- 慢性胰臟炎（CP）和囊性纖維化的盛行率不斷增加
- 人口老化加劇
- 診斷方面的進步
- 製藥業的技術進步
- 產業陷阱與挑戰
- 治療費用高
- 認知和教育有限
成長潛力分析
監管環境
技術景觀
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按處理方式，2021 - 2032 年

主要趨勢
營養管理
胰酵素替代療法（PERT）

第 6 章：市場估計與預測：按藥物類型，2021 - 2032 年

主要趨勢
克瑞翁
曾佩普
胰髒
烏特雷薩
維奧卡塞
其他藥物類型

第 7 章：市場估計與預測：按指標分類，2021 - 2032 年

主要趨勢
腹痛
便秘
腹瀉
脂肪糞便
減肥
其他適應症

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Abbott Laboratories
AbbVie Inc.
Allergan plc
Alexion Pharmaceuticals, Inc.
Anthera Pharmaceuticals Inc.
Amgen Inc.
AstraZeneca Plc
BioMarin Pharmaceutical Inc.
Cilian AG
Digestive Care, Inc.
Eli Lilly and Company
Johnson & Johnson
Nordmark Arzneimittel GmbH & Co. KG
Sanofi
Takeda Pharmaceutical Company Limited

簡介目錄

Product Code: 9379

Exocrine Pancreatic Insufficiency Treatment Market size is set to record 6.6% CAGR from 2024 to 2032 due to the rising geriatric population. Lately, clinicians are developing and refining therapies to improve digestive enzyme supplementation for better nutrient absorption. These treatments help to alleviate symptoms, such as malnutrition and gastrointestinal discomfort in elderly patients.

Lately, the ongoing research is enhancing enzyme formulations and delivery methods to personalize enzyme therapies tailored to individual patient needs as well as improved diagnostic tools for early detection and management of exocrine pancreatic insufficiency (EPI)-related complications. The World Population Prospects 2022 highlighted a faster growth rate among the population aged 65 years and older compared to younger age groups. This trend is underscoring the heightened emphasis on improving treatment for exocrine pancreatic insufficiency to better address the health needs of the elderly.

The exocrine pancreatic insufficiency treatment industry is segmented into treatment, drug type, indication, distribution channel, and region.

The market share from the nutritional management treatment segment will record a decent growth rate between 2024 and 2032. This treatment method involves tailoring diets and enzyme replacement therapies to individual patient needs to optimize nutrient absorption and alleviate symptoms like malnutrition and digestive discomfort. Specialists are refining these approaches for integrating dietary adjustments with enzyme supplements to enhance efficacy and patient well-being. Additionally, research efforts are leading to more targeted therapies with optimized treatment protocols to improve patient outcomes and quality of life.

In terms of distribution channels, the EPI treatment market from the online pharmacies segment is anticipated to witness a significant CAGR from 2024-2032. This is driven by the easy access to treatments for providing a convenient platform for patients to order prescription medications and enzyme supplements necessary for managing symptoms, such as malabsorption and digestive issues. Pharmacists and healthcare providers are actively leveraging these platforms to ensure timely delivery and patient education on treatment adherence.

Asia Pacific exocrine pancreatic insufficiency treatment industry size will record significant CAGR through 2032 due to improving healthcare infrastructure and ongoing drug development and innovation efforts. Healthcare facilities are actively upgraded to better diagnose and manage EPI for providing enhanced access to necessary medications and therapies. Researchers and pharmaceutical companies are developing new drugs and treatment protocols to improve efficacy and patient outcomes. Ongoing innovations in drug delivery systems and therapeutic approaches are ensuring that EPI patients in Asia Pacific receive state-of-the-art care with improved quality of life for individuals living with pancreatic insufficiency across the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.2 Increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis
- 3.2.3 Growing aging population
- 3.2.4 Advancements in diagnosis
- 3.2.5 Technological advancements in pharmaceutical industry
- 3.2.6 Industry pitfalls & challenges
- 3.2.7 High cost of treatment
- 3.2.8 Limited awareness and education
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Nutritional management
5.3 Pancreatic enzyme replacement therapy (PERT)

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Creon
6.3 Zenpep
6.4 Pancreaze
6.5 Ultresa
6.6 Viokace
6.7 Other drug types

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Abdominal pain
7.3 Constipation
7.4 Diarrhea
7.5 Fatty stools
7.6 Weight loss
7.7 Other indications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa